Table 1 Baseline characteristics of stroke patientsa
Baseline characteristics | All |
|---|---|
N | 4274 |
Age, years | 68 (61–76) |
Male gender | 2274 (53.2) |
BMI, kg/m2 | 26.2 (24.4–28.6) |
Vascular risk factors | |
 Hypertension | 1848 (43.2) |
 Diabetes mellitus | 1011 (23.7) |
 Hypercholesterolemia | 881 (20.6) |
 Atrial fibrillation | 842 (19.7) |
 Coronary heart disease | 1103 (25.8) |
Current smoking | 762 (17.8) |
 Previous CVD events | 791 (18.5) |
 Family history for stroke | 693 (16.2) |
 NIHSS score at admission | 7 (4–13) |
 DWI lesion size (N = 2812), ml | 21.3 (7.2–41.8) |
 Time to blood collection, hours | 5.2 (3.2–11.1) |
Stroke syndrome | |
 TACS | 966 (22.6) |
 PACS | 1650 (38.6) |
 LACS | 752 (17.6) |
 POCS | 906 (21.2) |
TOAST subtype | |
 Large-vessel disease | 756 (17.7) |
 Small-artery disease | 700 (16.4) |
 Cardioembolic | 1041 (24.4) |
 Multiple causes | 758 (17.7) |
 Other known | 558 (13.1) |
 Undetermined | 461 (10.8) |
Laboratory findings, serum levels | |
 Glucose, mmol/l | 6.3 (5.5–7.5) |
 Creatinine, mmol/l | 81.1 (69.0–95.0) |
 eGFR, e mL/min/1.73 m2 | 75.0 (60.8–91.9) |
 CRP, mg/l | 3.9 (2.4–9.5) |
 Copepin, pmol/l | 20.1 (14.9–28.3) |
 NT-ProBNP, pg/ml | 1111 (266–3722) |
 Adiponectin, μg/mL | 7.1 (4.8–9.8) |
Therapies before admission | |
 Aspirin | 900 (21.1) |
 Clopidogrel | 464 (10.9) |
 Anticoagulation | 855 (20.0) |
 Statins | 1302 (30.5) |
 Renin-angiotensin system blockers | 1541 (36.1) |
Acute treatment | |
 Endovascular/surgical revascularization | 312 (7.3) |